-
Pharmaceutical Giants Race to Integrate DeepSeek AI for Efficiency Gains
•
On February 14, China’s stock market saw a significant upsurge in the AI pharmaceuticals sector, with healthcare stocks across the board performing strongly. The rally was particularly driven by AI Pharmaceuticals, medical services, and DRG/DIP segments, with companies like Shanghai Runda Medical Technology Co., Ltd. leading the charge, resulting in…
-
ClouDr Group Integrates DeepSeeker R1 into CloudrBrain to Boost Chronic Disease Management
•
China-based ClouDr Group Limited (HKG: 9955) announced the integration of the DeepSeeker R1 model into its exclusive medical artificial intelligence (AI) product, CloudrBrain. The move aims to enhance CloudrBrain’s digital mining capabilities and improve the efficiency of chronic disease management through its hospital SaaS and pharmacy SaaS solutions. Enhancing AI-Driven…
-
ClouDr Receives NMPA Green Light for ClouDT-01, a Groundbreaking Digital Diabetes Treatment
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the banner of “ClouDr” on the Hong Kong stock exchange (HKG: 9955), has announced that it has secured marketing approval from the National Medical Products Administration (NMPA) for its innovative digital medicine product, ClouDT-01, designed for the treatment of diabetes. Leveraging…
-
ClouDr Partners with Hong Kong Magicure Medical Center to Enhance Cross-Border Medical Access
•
Hangzhou Kang Ming Information Technology Co., Ltd, known as “ClouDr” (HKG: 9955), has entered into a partnership with Hong Kong Magicure Medical Center with the goal of streamlining the supply chain and accelerating domestic access to the world’s leading medical resources in China. This collaboration aims to provide patients with…
-
ClouDr Partners with Banbiantian to Digitalize Medicine and Medical Device Sector
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the name “ClouDr” (HKG: 9955), has entered into a strategic partnership with Wuhan Banbiantian Medical Technology Development Co., Ltd. The collaboration, which is centered around digitalization technologies, is designed to capitalize on the “medicine, device, drug” linkage model. While financial specifics…
-
ClouDr Partners with Shaanxi Pharmaceutical Firms for Integrated Healthcare Solutions
•
Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), better known as “ClouDr,” has announced a strategic partnership with compatriot firms Shaanxi Pharmaceutical Holding Group Co., Ltd and Shaanxi Pharmaceutical Holding Pai Ang. The collaboration aims to leverage the respective resources and expertise of the three companies to enhance drug…
-
ClouDr Partners with Ipsen to Expand Diphereline’s Reach in China
•
Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), known as “ClouDr,” has partnered with French pharmaceutical company Ipsen S.A. (Euronext: IPN; ADR: IPSEY) regarding Ipsen’s Diphereline (triptorelin), a natural gonadotropin-releasing hormone (GnRH) agonist analog. Financial details of the partnership were not disclosed. ClouDr is a one-stop chronic disease management…
-
ClouDr Group’s Hong Kong IPO Nets HKD 482 Million with Sanofi as Investor
•
Hangzhou-based ClouDr Group Ltd (HKG: 9955), a one-stop chronic disease management and smart medical platform, has completed an initial public offering (IPO) on the Hong Kong Stock Exchange, raising HKD 482 million (USD 61.4 million). France-based pharmaceutical giant Sanofi acted as one of its cornerstone investors. Proceeds will be used…
